BVE
DeviceParticipants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)
NCT Number: NCT05073510
This is a BlueDop Vascular Expert System (BVE) Post-Market Clinical Follow-Up (PMCF) study. The primary objective of the study is to assess the clinical applicability and diagnostic accuracy of the BVE device in subjects who require an arterial duplex test due to suspected peripheral arterial disease (PAD).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hospital Los Madroños, Brunete, Madrid, Spain
The BVE device is intended to assess mean peripheral pressure, vascular reserve, Cuff free Ankle Brachial Index (ABIm), and assess the presence or absence of hemodynamically significant arterial disease. By converting Doppler shifts to a blood pressure measurement, BVE can be used to monitor PAD in a non-invasive manner without confounding by arterial calcification.
This is a post-market, interventional, prospective, multi-center, open-label, non-randomized, single-arm clinical investigation designed to evaluate the clinical equivalence of BVE to arterial Duplex in a group of patients referred for evaluation of PAD of the limbs when performed by a vascular specialist. Moreover, the evaluation of the clinical performance including inter-operator variability and BVE non-diagnostic rate will be also carried out as exploratory variables.
Evaluate the clinical equivalence (assessment of accuracy) of BVE as binary result (either presence or absence of significant peripheral arterial disease) compared to arterial duplex ultrasound in a group of patients referred for evaluation of PAD of the lower limbs when performed by a vascular specialist.
Evaluate the clinical equivalence (assessment of accuracy) of BVE as binary result (either presence or absence of significant peripheral arterial disease) compared to ankle brachial pressure index (ABPI) in a group of patients referred for evaluation of PAD of the lower limbs when performed by a vascular specialist.
Assess the safety of the BVE device.
Evaluation of the BVE System for clinical performance including time needed to perform BVE, inter-operator variability and number of BVE non-diagnostic tests.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)
Time frame: 1 day
Evaluation of clinical equivalence through a binary result (either presence or absence of significant PAD) in BVE compared to a binary summary of the arterial duplex.
Significant PAD is established with Duplex ultrasound when peak systolic velocity ratio (PSVR) is greater than 3 for any one level, or, if patients have multi-level disease, PSVR ≥ 2 at more than one level (i.e. sfa, pop)
Time frame: 1 day
Evaluation of clinical equivalence through a binary result (either presence or absence of significant PAD) in BVE compared to a binary summary of ABPI.
Significant PAD is established when ABPI index is <0.8.
Time frame: 1 day
Evaluation of BVE safety through the assessment of the risk and occurrence rates of AEs and SAEs
Time frame: 1 day
Comparison of the time to perform a vascular assessment using arterial duplex, BVE, and ABPI (when available).
Time frame: 1 day
Evaluation of clinical equivalence of BVE testing performed by staff specifically trained on BVE who are not vascular technologists/specialists compared to BVE testing performed by vascular technologists/specialists.
Time frame: 1 day
Number of patients and/or limbs that could not be assessed by BVE.
BlueDop Medical LTD
Industry
A Prospective, Multicenter, Nonrandomized, Open-label, Single-arm Study of the BlueDop Vascular Expert for Assessing Peripheral Arterial Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05858905
Arterial Occlusive Diseases, Arteriosclerosis
Palo Alto, California, United States
View Trial DetailsNCT05009862
Arterial Occlusive Diseases, Arteriosclerosis
Nashville, Tennessee, United States
View Trial DetailsNCT04130737
Arterial Occlusive Diseases, Arteriosclerosis
Mesa, Arizona, United States
View Trial DetailsNCT04283565
Arterial Occlusive Diseases, Arteriosclerosis
Saint-Etienne, France
View Trial Details